talking billions from 3 drugs in short term!

ATL1103 for Growth & Sight Disorders:

Market
Growth - Acromegaly

? A disorder of excess growth hormone and serum IGF-I in adults;

? Orphan drug indication (priority review/lower development costs/regulatory advantages);

? Neovascularisation of the retina leading to blindness;

? High prevalence: over 5 million Americans affected by diabetic retinopathy;

? No approved drug treatments for the advanced (proliferative) form of diabetic retinopathy; and

? Potential multi $Billion market.

and

ATL1101 -for Prostate Cancer

? ATL1101 has shown significant suppression of key tumour signalling pathways and prostate cancer tumour growth in animal studies. Select toxicology studies completed; and
? Oncology company currently testing ATL1101 in their cancer models for licensing.

and

ATL1102-for Multiple Sclerosis

? Successful Phase II trial confirming drug activity and safety in MS patients.

The Company is now seeking a new partner to continue the development, has received preliminary interest from other pharmaceutical companies.


Just remeber many years of trials and tests have all ready beeen spent getting it too this stage , not long before commercial stage!!

Same Blueprint of PRR ,but with 3 major drugs.

DYOR and check it at !!